

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5430284

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
WUXI BIOLOGICS (SHANGHAI) CO., LTD.	03/08/2019
WUXI BIOLOGICS IRELAND LIMITED	03/08/2019
OPEN MONOCLONAL TECHNOLOGY, INC.	03/08/2019
RECEIVING PARTY DATA	
Name:	WUXI BIOLOGICS IRELAND LIMITED
Street Address:	ONE SPENCER DOCK, NORTH WALL QUAY
City:	DUBLIN
State/Country:	IRELAND
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16334767
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	888 886 8168
Email:	patent@junhe.com
Correspondent Name:	JUN HE LAW OFFICES P.C.
Address Line 1:	2100 GENG ROAD
Address Line 2:	SUITE 102
Address Line 4:	PALO ALTO, CALIFORNIA 94303
ATTORNEY DOCKET NUMBER:	053674-8009US01
NAME OF SUBMITTER:	JAMES J. ZHU
SIGNATURE:	/James J. Zhu, Reg. No. 52,396/
DATE SIGNED:	03/20/2019
Total Attachments: 3	
source=3-WBP3015--Assignment--053674-8009WO02#page1.tif	
source=3-WBP3015--Assignment--053674-8009WO02#page2.tif	
source=3-WBP3015--Assignment--053674-8009WO02#page3.tif	

ASSIGNMENT

THIS ASSIGNMENT is made and entered into as of the 15th day of March, 2019 (the "Effective date") by and between WuXi Biologics (Shanghai) Co., Ltd., a legal entity existing under the laws of People's Republic of China, having an address at 299 Fute Zhong Road, Shanghai 200131, P. R. China, WuXi Biologics Ireland Limited, a legal entity existing under the laws of Republic of Ireland, having an address at One Spencer Dock, North Wall Quay, Dublin 1, Ireland, and Open Monoclonal Technology, Inc., a legal entity existing under the laws of the United States of America, having an address at 3911 Sorrento Valley Road, Suite 110, San Diego, California 92121, United States of America.

WuXi Biologics (Shanghai) Co., Ltd., WuXi Biologics Ireland Limited and Open Monoclonal Technology, Inc. are the co-owners of the patent application entitled NOVEL ANTI-PCSK9 ANTIBODIES, identified by International Patent Application No. PCT/CN2017/101357 filed on 12/09/2017 (date/month/year) (the "Application").

WuXi Biologics (Shanghai) Co., Ltd., WuXi Biologics Ireland Limited and Open Monoclonal Technology, Inc. (collectively the "Assignors") hereby assign to WuXi Biologics Ireland Limited (the "Assignee") the entire right, title and interest in and to the Application, and in and to any patents (collectively, "Patents") that may be granted for the Application worldwide.


For valuable consideration, the receipt and sufficiency of which Assignors acknowledge, Assignors hereby sell, assign, and transfer to Assignee, its successors, legal representatives and assign, any and all of our right, title and interest in and to: the Application, and any Patents; any divisions, continuations, and continuations-in-part of the Application, any other application claiming the same priority rights as the Application or claiming priority rights from the Application; any reissues, reexaminations, or extensions of any and all Patents; and the right to claim priority rights deriving from the Application (collectively, the "Rights"), whether now existing or hereafter arising. Assignors also agree to not sign any writing or do any act conflicting with this assignment, and, without further compensation, sign all documents and do such additional acts as Assignee deem necessary or desirable to:

8007


perfect Assignee's enjoyment of the Rights; prepare and prosecute the Application or any other applications for Patents; conduct proceedings regarding the Rights, including any litigation or derivation proceedings; or perfect or defend title to the Rights. Assignors request the Commissioner of Patents to issue any Patent or any other offices of similar authority to issue any Patents that may be issued on the Application to Assignee.

Assignor 1: WuXi Biologics (Shanghai) Co., Ltd.


Signature: 
 Name: CHRIS CHEN
 Title: CEO
 Date: _____



Assignor 2: WuXi Biologics Ireland Limited


Signature: 
 Name: CHRIS CHEN
 Title: CEO
 Date: _____

Assignor 3: Open Monoclonal Technology, Inc.

Signature: 
 Name: Charles Berkman
 Title: Vice President and Secretary
 Date: March 8, 2019

2007

Assignee: WuXi Biologics Ireland Limited.

Signature: 

Name: CHRIS CHEN

Title: CEO

Date: _____